Trends in Pharmacological Sciences
OpinionSpecial Issue: Rise of Machines in MedicineInsights into Computational Drug Repurposing for Neurodegenerative Disease
Section snippets
Computational Drug Repurposing Can Be a Fast and Cheap Tool for Drug Development
Neurodegenerative disease has posed significant and unique challenges to effective drug discovery over the past century. More than 5 million Americans are living with Alzheimer’s disease (AD) and more than 500 000 have been diagnosed with Parkinson’s disease (PD), the two most common neurodegenerative disorders 1., 2.. Millions more are suffering from rarer conditions, such as frontotemporal dementia (FTD), Huntington’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and
Existing Computational Approaches to Drug Repurposing
Previously, successful repurposed drugs came from serendipitous events in the laboratory and clinic. One relevant example of this is the use of zonisamide for the treatment of PD 18., 19.. Upon using zonisamide to treat a Japanese epilepsy patient with PD, Murata discovered that zonisamide also improved the patient’s PD symptoms [18]. Based on this serendipitous finding, zonisamide was approved as an anti-PD therapy in 2009 in Japan. Recently, the emergence of high-throughput molecular,
Lack of Validation Strategies and Economic Incentives Limits the Utility Computational Drug Repurposing for Neurodegenerative Disease
A major obstacle to computational drug repurposing for neurodegenerative disease is the lack of clear validation strategies. While all in silico strategies for computational drug repurposing require in vitro and in vivo experimental validation methods, this problem is more acute in the case of drug repurposing for complex and heterogeneous neurodegenerative disease. Unlike cancer, in which much progress has been made in modeling disease using highly-specific molecular subtype-related cell lines
Concluding Remarks and Future Perspectives
Computational drug repurposing strategies have the potential to dramatically reduce the time and cost of developing therapies for neurodegenerative disease. The advent of large-scale computing capacity combined with the creation of public transcriptomic databases such as CMap, large de-identified EMR databases, and large-scale structural data represent a unique opportunity to apply computational methods to discover novel drugs for neurodegenerative indications. In spite of these resources,
Acknowledgments
The authors thank members of the Sirota laboratory, especially Ishan Paranjpe, for their helpful discussions. M.S. and M.P. are supported by National Institute on Aging (NIA) 1R0AG057683 and R01AG060393. A.T. is supported by NIA F31AG058439.
Disclaimer Statement
Marina Sirota is a former employee of Pfizer and is a scientific advisor to twoXAR.
Glossary
- Artificial intelligence (AI)
- a field of computer science that develops computer systems which mimic human ability to problem solve and learn. Examples of AI relevant to computational drug repurposing include ML.
- Deeply learned autoencoder
- a type of AI model that seeks to determine efficient data encodings to represent data in a lower dimension and then reconstruct the original data. Denoising autoencoders introduce noise by randomly setting some of the input values to be missing and learn to
References (142)
Alzheimer’s disease: the next frontier—special report 2017
Alzheimers Dement.
(2017)Drug repositioning approaches for the discovery of new therapeutics for Alzheimer’s disease
Neurotherapeutics
(2015)A bibliometric review of drug repurposing
Drug Discov. Today
(2018)Zonisamide has beneficial effects on Parkinson’s disease patients
Neurosci. Res.
(2001)Age, APOE and sex: triad of risk of Alzheimer’s disease
J. Steroid Biochem. Mol. Biol.
(2016)Modeling spatial and temporal patterns of APOE ε4 mediated glucose uptake in mild cognitive impairment and normal controls
IFAC PapersOnLine
(2018)The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study
NeuroImage Clin.
(2019)NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease
Alzheimers Dement.
(2018)The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future
Genet. Med.
(2013)Pattern-based mining in electronic health records for complex clinical process analysis
Procedia Comput. Sci.
(2017)